Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition (PETANC)

August 16, 2017 updated by: Institut du Cancer de Montpellier - Val d'Aurelle

Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition Assessed by F-FDG Petscan

Evaluate the feasability to determine the difference of tumoral metabolism before and after artificial nutrition.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Evaluation of the feasability to determine the difference of tumoral metabolism before and after artificial nutrition. This activity will be measured with TEP/TDM 18F-FDG

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Montpellier, France, 34298
        • Icm Val D'Aurelle

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • VADS cancer or oesophageal cancer
  • Evaluation by 18F-FDG PET
  • denutrition with weight loss of 5%
  • Artificial nutrition
  • ECOG<2

Exclusion Criteria:

  • Treatment by chemotherapy, surgery unless 2 months
  • Treatment by radiotherapy unless 4 months
  • Capillar glycemia >12mmol/l during the PET

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: PET/TDM
Evaluation by PET/TDM at 2 times
Device: PET/TDM
Evaluation of nutrition absorption by TEP/TDM
Other Names:
  • Parenteral or enteral nutrition

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of Standardized Uptake Value (SUV)
Time Frame: 3 months
The variation of the SUVmax is defined as the difference of the tumoral SUV max between the TEP1 and the TEP2
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle

Investigators

  • Principal Investigator: DESHAYES Emmanuel, ICM Co. Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2013

Primary Completion (Actual)

November 1, 2015

Study Completion (Actual)

August 9, 2017

Study Registration Dates

First Submitted

February 4, 2014

First Submitted That Met QC Criteria

March 2, 2015

First Posted (Estimate)

March 6, 2015

Study Record Updates

Last Update Posted (Actual)

August 21, 2017

Last Update Submitted That Met QC Criteria

August 16, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ICM2013/31

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Head and Neck Cancer

Clinical Trials on PET/TDM

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe